Risk factors for mortality in AAV-ILD included age, a history of smoking, a UIP pattern, acute exacerbations of ILD, and the microscopic polyangiitis subtype.

Researchers found that use of immunosuppressive medication was a strong protective factor, associated with a 60% reduction in ...

I don’t think an algorithm can re-create the specifically human experiences” of penning a physician note that will be ...

Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...

Discover why difficult breathing might indicate heart disease, lung conditions, anxiety disorders, or blood problems, and ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Mr. A, an office worker in his late 30s, recently had a drinking party with his colleagues and drank too much. The next day, I visited the emergency room with symptoms of nausea, vomiting, hand ...

The study highlighted the significant benefits of long-term oxygen therapy in reducing total and hospitalized acute ...

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and ...

ABSTRACT: Introduction: Interstitial lung disease (ILD) is a progressive pulmonary disease, and many patients with ILD eventually require long-term oxygen therapy (LTOT) despite intensive treatment.